CG Oncology Inc. has made a strategic move by shifting its headquarters from Irvine, California, to Dallas, Texas. The company’s previous local office will close as its lease concludes at the end of August.
New Beginnings in Dallas
Last December, CG Oncology secured an eight-year lease for new office space at Pegasus Park, a thriving 23-acre life sciences and innovation campus in Dallas. This move positions the company amidst a dynamic community of researchers, investors, and innovators.
Arthur Kuan, the chairman and CEO of CG Oncology, expressed enthusiasm about the new campus. He highlighted the benefits of being in a collaborative environment within the life sciences ecosystem. Kuan noted, “Pegasus Park is an ideal setting for us as we continue to develop our innovative immunotherapy for bladder cancer patients.”
Expanding Presence
In addition to its Dallas headquarters, CG Oncology holds office spaces in Emeryville, California, and Branchburg, New Jersey. As of last year, the company employed 61 individuals, operating from a modest 1,249-square-foot office in Irvine. It remains unclear if CG Oncology plans to retain any presence in Orange County.
Progress in Clinical Trials
Founded in 2010, CG Oncology is nearing the commercialization of its primary immunotherapy, known as cretostimogene grenadenorepvec, which employs genetically modified viruses to target bladder tumors. Despite being pre-revenue, the company has garnered significant investor confidence. Recently, its shares reached an all-time high of $80.97, with the market capitalization swelling to $7.1 billion over the past year.
Bladder cancer affects over 763,000 individuals in the U.S., making it the sixth most common cancer nationwide. According to estimates from the American Cancer Society, 84,530 new cases are expected to be diagnosed in 2026, with over 17,000 fatalities predicted.
Upcoming Data and Trials
In August, CG Oncology announced its intention to release topline data from its Phase 3 Pivot-006 trial in the near future. This trial compares the efficacy of cretostimogene with standard surveillance in patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC) after tumor removal. Kuan remarked, “PIVOT-006 has accrued the vast majority of the target events, and we look forward to sharing topline results soon.”
The company recently published results from another Phase 3 clinical trial in The Lancet Oncology, revealing a 75.5% remission rate for patients with high-risk NMIBC. Notably, 89% of participants were able to preserve their bladders after 12 months, and 81% maintained bladder integrity at the 24-month mark.
CG Oncology aims to finalize its biologics license application (BLA) submission by the end of this year. A recent filing disclosed that the company possesses $1 billion in cash and equivalents, although it reported a net loss of $79.1 million for the second quarter. In previous years, CG has generated approximately $25 million in research and collaboration revenue through various license and collaboration agreements.
A Thriving Life Sciences Community
CG Oncology joins a burgeoning group of life sciences companies at Pegasus Park, which houses over 50 tenants, including 20 startups within its BioLabs incubator. The healthcare investment firm Highlander Health Partners has also expanded its operations at the same facility. Additionally, LH Capital, the investment branch of Lyda Hill Philanthropies, will be establishing a presence at Pegasus Park.
Lyda Hill, an entrepreneur and philanthropist, has invested significantly in cancer research, STEM education, and various community initiatives, further contributing to the growth of the life sciences ecosystem in Dallas.
Conclusion
CG Oncology’s relocation to Dallas marks a pivotal chapter in its journey towards advancing bladder cancer treatment. This strategic move enhances its collaborative potential within a vibrant life sciences community. As the company approaches significant clinical milestones, its innovative spirit remains a beacon of hope for patients battling bladder cancer.
- CG Oncology has relocated its headquarters from Irvine to Dallas.
- The company focuses on developing an immunotherapy for bladder cancer.
- Recent trials show promising results for patients with high-risk NMIBC.
- CG Oncology has a strong financial position with $1 billion in cash.
- Pegasus Park is becoming a hub for life sciences innovation.
Read more → www.ocbj.com